{"id":"W3211938324","doi":"10.1016/j.eururo.2021.10.001","title":"First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial","year":2021,"lang":"en","type":"article","venue":"European Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"University of Texas MD Anderson Cancer Center; Bristol-Myers Squibb; Ono Pharmaceutical; National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; European Society for Medical Oncology","keywords":"Medicine; Nivolumab; Sunitinib; Ipilimumab; Nephrectomy; Urology; Internal medicine; Second line; Kidney cancer; Renal cell carcinoma; Oncology; First line; Surgery; Kidney; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007155209,0.0002547635,0.0004733578,0.0001433944,0.0000739442,0.00002980576,0.0001496202,0.00004862758,0.0000850733],"category_scores_gemma":[0.0001745277,0.0001759247,0.00004525006,0.0002910032,0.0001440685,0.00008714921,0.0001122484,0.0004164506,0.00003335295],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001627251,"about_ca_system_score_gemma":0.0002344133,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008494702,"about_ca_topic_score_gemma":0.0005470426,"domain_scores_codex":[0.9970987,0.001227515,0.0004007543,0.0005302257,0.0003263353,0.0004164989],"domain_scores_gemma":[0.9989254,0.0002011477,0.0001211966,0.0005334275,0.00009806443,0.000120701],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.784222,0.003670401,0.1830577,0.0001817751,0.0002571683,0.01680667,0.004037666,0.0006622876,0.000344932,0.00007186512,0.0003263592,0.00636118],"study_design_scores_gemma":[0.3172165,0.01944311,0.6559257,0.00005654362,0.000256594,0.0003802829,0.0001617575,0.0004838739,0.0001094612,0.00001540048,0.005698394,0.0002523424],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980426,0.0002948946,0.000004206917,0.000458566,0.000156911,0.0009246746,0.00000664322,0.00003278861,0.01769529],"genre_scores_gemma":[0.9978949,0.00002978075,0.0003413882,0.001003662,0.000196595,0.0000363082,0.0001847853,0.00005621655,0.0002563182],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.472868,"threshold_uncertainty_score":0.7174002,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03503532779758081,"score_gpt":0.2654187618524622,"score_spread":0.2303834340548813,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}